Evolution of cell & gene therapy in China: the case for universal CAR-T
China now represents 60% of clinical development in CAR-T therapy development globally: what have we learned to date and where are future opportunities?
Accelerating clinical development in China & the US
China and the US are the world’s largest oncology research destinations, and the clinical research bridge between them supports accelerated clinical development from early to late phase trials while ensuring the inclusion of MRCT data packages in future regulatory applications.
Development and Regulatory Strategy for US and China
This webinar discusses the expansion of International Market for Ensartini and RNAi Therapeutics in Oncology, from Skin Cancers to Liver Cancers. Additionally, it aims to understand the Evolving U.S. regulatory requirements for diversity in clinical cancer trials.
Go/No Go Decisions Based on Early Phase Oncology Trials
Understanding the latest regulatory and clinical developments in the field of Oncology in China, along with discussing the similarities and differences between Chinese oncology market and the overall global market, promote academic exchange and cooperation of the global oncology research and development ecosystem.
Driving efficiencies through virtual trial solutions in Asia Pacific
What is driving the acceleration of clinical trials in the Asia Pacific region and what are key considerations to maximise the opportunity for decentralised clinical trials in the future across the region.
Accelerating Clinical Trials in Rare Disease - Understanding Asia’s success as a rare disease clinical trial location
This webinar looks at Asia’s rare disease clinical trial landscape, why China is an increasingly attractive location for rare disease trials and critical program strategies to consider.
Expedited clinical development strategies for China
A two-part webinar interview and panel discussion with exclusive insights into China’s regulatory environment, the advantages of involving China sites, and strategies to accelerate entry in China.
由 Katrina Norial 在 OCT Southeast 上发表。在此演讲中， Katrina Norial 讨论了 Novotech 的能力，如何确保 COVID-19 期间临床试验的连续性，以及如何利用区域优势加速临床试验开发。
Managing Global Studies with Regional Partners
In this webinar, you'll learn about 1) Working with specialist CRO partners to maintain speed, flexibility, “fit” and regional expertise, 2) Leveraging technology and gold standard systems to provide integrated global management structure and reporting and 3) Advantages and tradeoffs of different global clinical trial setups.